Ingenia Therapeutics Goes Public to Accelerate Vascular Therapies
BOSTON, Massachusetts, and Seoul, South Korea — August 18, 2026 Ingenia Therapeutics announced that its shares have begun trading...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BOSTON, Massachusetts, and Seoul, South Korea — August 18, 2026 Ingenia Therapeutics announced that its shares have begun trading...
HERZLIYA, ISRAEL — December 5, 2025 — Regentis Biomaterials Ltd., a regenerative medicine MedTech company developing innovative tissue-repair solutions,...
